Strata Critical Medical Announces Second Quarter 2026 Results
Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clini
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the disclosed Q2 revenue, adjusted EBITDA, operating cash flow, and free cash flow, and incorporate the Statline transplant placement relationship transfer as an incremental growth lever over the next year.
Market read
Fresh quarterly financials with improved adjusted profitability plus a newly signed commercial relationship transfer provide actionable inputs for SRTA positioning.
What to watch
Adjusted EBITDA and free cash flow are non-GAAP; integration costs, amortization of intangibles, and customer concentration in transplant center vs OPO segments could affect forward results.
Background
The 8-K (Item 2.02) reports Strata Critical Medical’s second quarter 2026 results and includes an update on clinical services expansion via acquisitions and a newly signed customer-relationship agreement.
Ticker impact
Strata reported Q2 2026 revenue of $72.5M (+60.7% YoY), adjusted EBITDA of $7.9M, and signed a deal to take over Statline transplant placement relationships.
Near-term upside bias as traders price in margin expansion and incremental transplant ecosystem revenue from the Statline relationship transfer.
The filing provides fresh, quantified operating and cash-flow metrics plus a newly signed customer-relationship agreement, both of which can drive earnings-multiple repricing and forward revenue expectations.
Market effects
Supports the narrative that transplant-adjacent clinical services are scaling with better margins, potentially improving sentiment toward similar healthcare services roll-ups.
No clear regional read-through beyond US healthcare services demand.
Limited global impact; largely US transplant logistics and clinical services.
Counterpoint
GAAP net loss widened materially, and clinical revenue is newly reflected due to acquisitions and reclassification, so the quality and durability of margins may be questioned.
Key entities
- issuerStrata Critical Medical, Inc.
Nasdaq-listed company reporting Q2 2026 results and expansion in transplant clinical services.
- counterpartyStatline
Company whose transplant center organ placement customer relationships Strata agreed to take over on a rolling basis over the next year.
